CD16

Revision as of 16:12, 27 February 2017 by en>Rod57 (→‎Function: ==As a drug target== Margetuximab targets CD16A in preference to CD16B.<ref)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Fc fragment of IgG, low affinity IIIa, receptor (CD16a)
Identifiers
SymbolFCGR3A
Alt. symbolsFCGR3, FCG3
Entrez2214
HUGO3619
OMIM146740
RefSeqNM_000569
UniProtP08637
Other data
LocusChr. 1 q23
Fc fragment of IgG, low affinity IIIb, receptor (CD16b)
Identifiers
SymbolFCGR3B
Alt. symbolsFCGR3, FCG3
Entrez2215
HUGO3620
OMIM610665
RefSeqNM_000570
UniProtO75015
Other data
LocusChr. 1 q23

CD16 is a low affinity Fc receptor.

It is a cluster of differentiation molecule found on the surface of natural killer cells, neutrophil polymorphonuclear leukocytes, monocytes and macrophages.[1] It can be used to isolate populations of these cells by antibodies directed towards CD16, using fluorescent-activated cell sorting or magnetic-activated cell sorting.

Function

CD16 has been identified as Fc receptors FcγRIIIa (CD16a) and FcγRIIIb (CD16b). These receptors bind to the Fc portion of IgG antibodies which then activates the NK cell for antibody-dependent cell-mediated cytotoxicity. A lack of CD16 in a given population of neutrophils may indicate prematurity, as could be caused by a left shift due to neutrophilic leukocytosis induced by tissue necrosis or bacterial infection.[2]

As a drug target

Margetuximab targets CD16A in preference to CD16B.[3]

References

  1. Janeway, Charles (2001). "Appendix II. CD antigens". Immunobiology (5 ed.). New York: Garland. ISBN 0-8153-3642-X.
  2. Vidranski, V; Laskaj, R; Sikiric, D; Skerk, V (2015). "Platelet satellitism in infectious disease?". Biochem Med (Zagreb). 25: 285–94. doi:10.11613/BM.2015.030. PMC 4470096. PMID 26110042.
  3. "Margetuximab". AdisInsight. Retrieved 1 February 2017.

External links